Ana Beatris Rossi (A B Rossi, Ana B Rossi)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 20

Top Topics

Atopic Dermatitis

Top Venues

Dermatology and therapy

The British journal of dermatology

Experimental dermatology

American journal of clinical dermatology

This page only lists publications with an associated author ORCID identifier.

Publications

Mike Bastian, Nick Freemantle, Ana Beatris Rossi, Brad Shumel, Gaelle Bego Le Bagousse, Zhixiao Wang, Yingxin Xu, Patricia Guyot
Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab Versus Dupilumab in Moderate-to-Severe Atopic Dermatitis'. Dermatology and therapy 14 (3) (2024)
Mike Bastian, Nick Freemantle, Ana Beatris Rossi, Brad Shumel, Gaelle Bego Le Bagousse, Zhixiao Wang, Yingxin Xu, Patricia Guyot
Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab Versus Dupilumab in Moderate-to-Severe Atopic Dermatitis'. Dermatology and therapy (2024)
Mike Bastian, Nick Freemantle, Ana Beatris Rossi, Brad Shumel, Gaelle Bego Le Bagousse, Zhixiao Wang, Yingxin Xu, Patricia Guyot
Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab Versus Dupilumab in Moderate-to-Severe Atopic Dermatitis'. Dermatology and therapy 14 (3) (2024)
Mike Bastian, Nick Freemantle, Ana Beatris Rossi, Brad Shumel, Gaelle Bego Le Bagousse, Zhixiao Wang, Yingxin Xu, Patricia Guyot
Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab Versus Dupilumab in Moderate-to-Severe Atopic Dermatitis'. Dermatology and therapy 14 (3) (2024)
Mike Bastian, Nick Freemantle, Ana Beatris Rossi, Brad Shumel, Gaelle Bego Le Bagousse, Zhixiao Wang, Yingxin Xu, Patricia Guyot
Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab Versus Dupilumab in Moderate-to-Severe Atopic Dermatitis'. Dermatology and therapy (2024)
Mike Bastian, Nick Freemantle, Ana Beatris Rossi, Brad Shumel, Gaelle Bego Le Bagousse, Zhixiao Wang, Yingxin Xu, Patricia Guyot
Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab Versus Dupilumab in Moderate-to-Severe Atopic Dermatitis'. Dermatology and therapy 14 (3) (2024)
Mike Bastian, Nick Freemantle, Ana Beatris Rossi, Brad Shumel, Gaelle Bego Le Bagousse, Zhixiao Wang, Yingxin Xu, Patricia Guyot
Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab Versus Dupilumab in Moderate-to-Severe Atopic Dermatitis'. Dermatology and therapy 14 (3) (2024)
Iria Neri, Elena Galli, Ilaria Baiardini, Mario Picozza, Ana Beatris Rossi, Paolo Matruglio, Devis Moretti, Filippo Cipriani
Implications of Atopic Dermatitis on the Quality of Life of 6-11 Years Old Children and Caregivers (PEDI-BURDEN). Journal of asthma and allergy 16 (2023)
Jonathan Ian Silverberg, Mark Boguniewicz, Jon Hanifin, Kim A Papp, Haixin Zhang, Ana Beatris Rossi, Noah A Levit
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis is Efficacious Regardless of Age of Disease Onset: a Post Hoc Analysis of Two Phase 3 Clinical Trials. Dermatology and therapy 12 (12) (2022)
Evgeny V Berdyshev, Elena Goleva, Robert Bissonnette, Irina Bronova, Anna Sofia Bronoff, Brittany N Richers, Shannon Garcia, Marco Ramirez-Gama, Patricia Taylor, Amy Praestgaard, Inoncent Agueusop, Pauline Jurvilliers, Mark Boguniewicz, Noah A Levit, Ana Beatris Rossi, Annie Zhang, Donald Y M Leung
Dupilumab significantly improves skin barrier function in patients with moderate-to-severe atopic dermatitis. Allergy 77 (11) (2022)
Gil Yosipovitch, Marjolein de Bruin-Weller, April W Armstrong, Jashin J Wu, Pedro Herranz Pinto, Diamant Thaҫi, Dimittri Delevry, Gaëlle Bégo-Le Bagousse, Raymond Zhang, Brad Shumel, Ana Beatris Rossi, Jingdong Chao
Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis. Dermatology and therapy 11 (6) (2021)
Marjolein de Bruin-Weller, Joseph Frank Merola, H Chih-Ho Hong, Esther Serra Baldrich, Karel Ettler, Debra Sierka, Dimittri Delevry, Zhen Chen, Ana Beatris Rossi
Efficacy of Dupilumab in Atopic Dermatitis: The Patient's Perspective. Dermatology and therapy 11 (6) (2021)
Christopher Ernest Maitland Griffiths, Marjolein de Bruin-Weller, Mette Deleuran, Maria-Concetta Fargnoli, Delphine Staumont-Sallé, H Chih-Ho Hong, Jose Sánchez-Carazo, Peter Foley, Seong Jun Seo, Jérôme Msihid, Zhen Chen, Sonya L Cyr, Ana Beatris Rossi
Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials. Dermatology and therapy 11 (4) (2021)
A S Paller, J K L Tan, J Bagel, Ana Beatris Rossi, Brad Shumel, H Zhang, A Abramova
IGAxBSA composite for assessing disease severity and response in patients with atopic dermatitis. The British journal of dermatology (2021)
Amy S Paller, Ashish Bansal, Eric L Simpson, Mark Boguniewicz, Andrew Blauvelt, Elaine C Siegfried, Emma Guttman-Yassky, Thomas Hultsch, Zhen Chen, Paola Mina-Osorio, Yufang Lu, Ana Beatris Rossi, Xinyi He, Mohamed Kamal, Neil M H Graham, Gianluca Pirozzi, Marcella Ruddy, Laurent Eckert, Abhijit Gadkari
Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial. American journal of clinical dermatology 21 (1) (2020)
Marius Ardeleanu, Brad Shumel, Ana Beatris Rossi, N M H Graham
Response to R. Waldman et al.: 'Does IL-4 inhibition play a role in dupilumab-associated conjunctivitis?' The British journal of dermatology 182 (5) (2020)
Sébastien Barbarot, Andreas Wollenberg, Jonathan Ian Silverberg, Mette Deleuran, Giovanni Pellacani, J C Armario-Hita, Z Chen, B Shumel, L Eckert, A Gadkari, Y Lu, Ana Beatris Rossi
Dupilumab provides rapid and sustained improvement in SCORAD outcomes in adults with moderate-to-severe atopic dermatitis: combined results of four randomized phase 3 trials. The Journal of dermatological treatment (2020)
Andreas Wollenberg, L A Beck, Andrew Blauvelt, E L Simpson, Z Chen, Q Chen, B Shumel, F A Khokhar, T Hultsch, E Rizova, Ana Beatris Rossi, N M H Graham, G Pirozzi, Y Lu, M Ardeleanu
Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). The British journal of dermatology 182 (5) (2019)
Virginie Ribet, Vincenzo Nobile, Ana Beatris Rossi
In situ antioxidant activity of a dermo-cosmetic product: A randomized controlled clinical study. Experimental dermatology 28 (11) (2019)
Jonathan Ian Silverberg, E L Simpson, M Ardeleanu, D Thaçi, Sébastien Barbarot, J Bagel, Z Chen, Laurent Eckert, J Chao, A Korotzer, E Rizova, Ana Beatris Rossi, Y Lu, N M H Graham, T Hultsch, G Pirozzi, B Akinlade
Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials. The British journal of dermatology 181 (1) (2019)